Overview:

Single photon emission computed tomography (SPECT) is a form of non-invasive nuclear medicine tomographic imaging technique that utilizes gamma rays to provide 3D information of body organs (inside view). This system uses a radioactive substance and a special camera to create 3-D pictures which display the blood flow to tissues & organs thereby assisting doctors to diagnose or monitor brain disorders, bone disorders, and heart problems. The SPECT scan integrates two technologies: computed tomography (CT) and a radioactive material (tracer). Worldwide growing geriatric population coupled with rising prevalence of chronic diseases are majorly driving the demand for SPECT systems. Furthermore, technological developments in SPECT systems, development of new radiotracers, increasing investments for the advancement of diagnostic imaging centers and increasing awareness among people about the technology is expected to assist in the market growth. On the contrary, factors such as a requirement of massive capital, the presence of alternatives like scintigraphy & positron emission tomography (PET), high operation costs, and an immature reimbursement structure are anticipated to limit the utilization of SPECT technique over the forecast period.

The standalone SPECT systems are gaining traction worldwide thereby expected to exhibit favorable market growth during the forecast period. Based on application, the oncology segment is expected to dominate the market over the next nine years owing to growing prevalence of cancer across the world. Comparatively higher adoption or utilization of SPECT technique in hospitals shall put the hospitals segment at the dominant position.

North America is likely to hold a large chunk of the market due to the presence of major market participants & sophisticated healthcare infrastructure and comparatively higher adoption of advanced nuclear medicine tomographic imaging techniques in the U.S. and Canada. Asia Pacific to witness fastest market growth in the near future attributed to growing aging population along with a surge in the incidence of chronic diseases, rising awareness about technique, and increasing healthcare spending in China, India, and Japan.

The global single photon emission computed tomography market is segmented on the following bases:

• Global Single Photon Emission Computed Tomography Market, by Product Type, 2016-2026 (US$ Mn)
  • Hybrid SPECT Systems
  • Standalone SPECT Systems
• Global Single Photon Emission Computed Tomography Market, by Application, 2016-2026 (US$ Mn)
  • Oncology
  • Cardiology
  • Neurology
  • Others
• Global Single Photon Emission Computed Tomography Market, by End User, 2016-2026 (US$ Mn)
  • Hospitals
  • Diagnostic Imaging Centers
  • Academic & Research Centers
  • Others
• Global Single Photon Emission Computed Tomography Market, by Geography, 2016-2026 (US$ Mn)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • Japan
    • China
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa (MEA)
    • GCC
    • Rest of MEA

Key players identified in the global single photon emission computed tomography market include:

• GE Healthcare
• Philips Healthcare
• Siemens Healthineers
• Digirad Corporation
• Bruker Corporation
• NuCare Inc.
• PNPMed
• SurgicEye GmbH
• DDD-Diagnostic A/S
• Mediso Ltd.

This report offers:

• Comprehensive overview of the global single photon emission computed tomography market including the current & future market dynamics
• Elucidation of each market segment based on recent product approvals, launch, and current and anticipated market dynamics
• Company profiles and competitive landscape of the leaders operating in the single photon emission computed tomography market comprising key products, operating business areas, financial analysis, and recent strategic developments